ISOXSUPRINE HYDROCHLORIDE- isoxsuprine hydrochloride tablet Vista Pharmaceuticals, Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.


ISOXSUPRINEHYDROCHLORIDE TABLETS, USP

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA.

CAUTION: Federal Law prohibits dispensing without prescription

DESCRIPTION

Isoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter taste, It has a following structural formula



INDICATIONS

Based on a review of this drug by the National Academy of Sciences -National Research Council and / or other information, the FDA has classified the medications as follows :

Possibly Effective :

1. For the relief of symptoms associated with cerebral vascular insufficiency

2. In Peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's Disease) and Raynaud's disease.

Final classification of the less-than-effective indications requires further investigation.

COMPOSITION

Each tablet contains lsoxsuprine HCI 20 mg.

These tablets contain the following inactive ingredients: dibasic calcium phosphate (anhydrous), lactose, magnesium stearate. microcrystalline cellulose, povidone k30, and sodium starch glycolate.

DOSAGEANDADMINISTRATION

Oral:10 to 20 mg three or four times daily

CONTRAINDICATIONS AND CAUTIONS

Oral

There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding.

ADVERSE REACTIONS

On rare occasion, oral administration of the drug has been associated in time with the occurrences of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued.

Although available evidence suggests a temporal association of these reactions with isoxsuprine, a casual relationship can be neither confirmed nor refuted.

 β -Adrenergic receptor stimulants such as isoxsuprine hydrochloride have been used to inhibit pre-term labor. Maternal and fetal tachycardia may occur under such use. Hypocalcemia, hypoglycemia, hypotension and ileus have been reported to occur in infants whose mothers received isoxsuprine. Pulmonary edema has been reported in mothers treated with β -stimulants. Isoxsuprine HCl tablets, USP is neither approved nor recommended for use in the treatment of premature labor.

HOW SUPPLIED

Isoxsuprine HCI tablets, USP are supplied in HDPE bottles.

20 mg Bottles of 1,000's: NDC61971-065-10

Manufactured in India by Vista Pharmaceuticals, Limited.

For Vista Pharmaceuticals, Inc. Revised:07/2017



ISOXSUPRINE HYDROCHLORIDE

isoxsuprine hydrochloride tablet

Product Information

Product Type

HUMAN PRESCRIPTION DRUG

Item Code (Source)

Route of Administra	tion	ORAL					
. . 1							
Active Ingredient		•					
	Ingredient Name			Basis of Strength		Strength	
lsoxsuprine hydrochlo	oride (UNII: V74	TEQ36CO) (Isoxsuprine - UNII:R15UI32	245N)	Isoxsuprine hydi	o chlo ride	20 mg	
Inactive Ingredie	nts						
				Strength			
LACTOSE (UNII: J2B2)	A4N98G)						
CELLULOSE, MICRO	CRYSTALLINE	(UNII: OP1R32D61U)					
CALCIUM PHO SPHAT	TE, DIBASIC, AN	NHYDROUS (UNII: L11K75P92J)					
POVIDONE K30 (UNII	: U725QWY32X)						
SODIUM STARCH GL	YCOLATE TYP	E A POTATO (UNII: 5856J3G2A2)					
MAGNESIUM STEARA	TE (UNII: 7009	7M6I30)					
Product Characte	ristics						
Color	white	Score	Score 2 pieces				
Shape	ROUND	Size	ize 10 mm				
Flavor		Imprint Code	Imprint Code 20;VISTA065				
Contains							
Packaging							
# Item Code	Package Description		Marketin	Marketing Start Date		Marketing End Date	
1 NDC:61971-065-10	1000 in 1 BOTT	LE; Type 0: Not a Combination Product	t 09/19/1997	,			
Marketing Info	ormation						
Marketing Category		on Number or Monograph Citation	Marketin	ig Start Date	Marketin	g End Date	
5 5 7				09/19/1997			
unapproved drug other			09/19/1997	,			

Labeler - Vista Pharmaceuticals, Inc. (943932806)

Establishment							
Name	Address	ID/FEI	Business Operations				
Vista Pharmaceuticals, Limited.		916648541	manufacture(61971-065), analysis(61971-065)				

Revised: 1/2020

Vista Pharmaceuticals, Inc.